Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is a biopharmaceutical company with a robust portfolio of gene therapy platforms and clinical programs targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company's lead product, Papzimeos, showed durable complete responses after a single treatment in a pivotal study with no reported safety issues. In addition, the FDA granted Papzimeos orphan-drug market exclusivity in adult RRP, providing a competitive advantage in a small rare-disease market. With positive ASCO durability data and an upcoming PRGN-2009 Phase 2 update, the company is well-positioned for continued success and potential future growth.

Bears say

Precigen is facing significant risks and challenges, including clinical and regulatory hurdles in developing and commercializing their gene therapy products. Despite potential label expansion opportunities, the company has yet to generate positive earnings and has a high debt level. Furthermore, the success of their products ultimately depends on obtaining regulatory approvals and maintaining successful partnerships, which are key areas of risk for the company.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.